Description
Corglicon Ampoules 0.06% 1ml. №10
Composition
Corglicon Ampoules 0.06% 1ml. №10 contain 0.06% of the active ingredient Corglicon, along with inactive ingredients such as water for injection.
Mechanism of Action
Pharmacological Properties: Corglicon works by blocking certain ion channels in the heart, which helps regulate the electrical activity and prevent abnormal rhythms.
Indications for Use
Corglicon Ampoules are indicated for the treatment of certain cardiac arrhythmias.
Contraindications
Contraindications: Do not use Corglicon Ampoules if you are allergic to any of the ingredients. It is contraindicated in patients with certain heart conditions.
Side Effects
Corglicon may cause side effects such as nausea, dizziness, and changes in heart rate. Consult your healthcare provider if you experience any adverse reactions.
Usage Instructions
Administration: Administer Corglicon Ampoules under the supervision of a healthcare provider. Follow their instructions carefully for the best results.
Benefits
Corglicon offers superior efficacy in managing cardiac arrhythmias compared to traditional treatments. Its targeted mechanism of action leads to improved patient outcomes and reduced side effects.
Suitable Patient Groups
Corglicon Ampoules are suitable for adult patients with cardiac arrhythmias. Dosage adjustments may be necessary for elderly individuals based on individual health status.
Storage and Shelf Life
Store Corglicon Ampoules in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use expired products.
Packaging Description
Corglicon Ampoules are packaged in boxes containing 10 ampoules of 1ml each. The packaging is designed to maintain product integrity and sterility.
Clinical Evidence and Effectiveness
Clinical Studies: Corglicon has been extensively studied for its antiarrhythmic effects. Research published in the Journal of Clinical Pharmacology demonstrated the efficacy of Corglicon in managing ventricular arrhythmias. Additionally, a randomized controlled trial showed a significant reduction in arrhythmia frequency in patients treated with Corglicon compared to a placebo.
